RealVNC mid banner careers
Advertisement: Mogrify mid banner
Advertisement: CBM
Barr Ellison Solicitors – commercial property
Advertisement: RSM
RealVNC mid-banner general
Advertisement: Lynch Wood Park
ARM Innovation Hub
Advertisement: Cambridge Network
Advertisement EY mid
Advertisement Cambridge China Centre
Advertisement: Bridge Fibre mid
Advertisement: Bradfield Centre mid
5 December, 2014 - 12:00 By News Desk

Clinical trials boost via Linguamatics-Thomson Reuters alliance

Linguamatics John Brimacombe

A technology collaboration between Cambridge UK text analytics specialist Linguamatics and the IP and science business of Thomson Reuters in Philadelphia will lead to more effective clinical trials and drug discovery, the partners believe.

The collaboration is designed to advance pharmaceutical clinical trial R & D with the launch of Cortellis Informatics Clinical Text Analytics for I2E.

The new solution, available through Thomson Reuters Cortellis – described by the partners as ‘the most powerful intelligence platform for life science professionals’ – applies Linguamatics’ I2E text mining platform to relevant information to assist researchers in finding actionable insights. 

The content includes clinical trial information, epidemiology data, literature, press releases and conference proceedings.

Cortellis Informatics Clinical Text Analytics for I2E uses the combination of Linguamatics’ powerful, market-leading NLP text analytics platform with the largest breadth and depth of integrated clinical content available. 

Through a single interface, users will be able to glean new insights in support of trials, site selection and competitive intelligence, helping them to design more effective clinical trials and gain a deeper understanding of the implications of their results.

“We are excited about this innovative project with Thomson Reuters‚” said John Brimacombe, executive chairman of Linguamatics. “Combining the strength of our best of breed text analytics with the wealth of content within Cortellis will be a significant step forward for our clients in advancing productivity and efficacy in pharmaceutical R & D.”

Jon Brett-Harris, managing director of Thomson Reuters Life Science business, added: “We are pleased to be working with Linguamatics to provide the pharmaceutical industry with a solution that leverages the leading capabilities of both organisations and will provide our mutual customers with a stronger view into the clinical trial process. 

“Our joint solution will make it easier for researchers to obtain the insights they need to help them make decisions that optimise the drug development process.”

Linguamatics is marketed as the world leader in deploying innovative natural language processing (NLP)-based text mining for high-value knowledge discovery and decision support. 

Its technology is used by top commercial, academic and government organisations, including 17 of the top 20 global pharmaceutical companies, the US Food and Drug Administration and leading US healthcare providers. 

I2E can be used to mine a wide variety of text resources, such as scientific literature, patents, Electronic Health Records (EHRs), clinical trials data, news feeds, social media and proprietary content. I2E can be deployed as an in-house enterprise system, an add-on to enterprise search, or as Software-as-a-Service (SaaS) on the cloud.

Linguamatics won the Queen’s Award for Enterprise 2014 for International Trade in April.


• PHOTOGRAPH SHOWS: John Brimacombe

Add new comment

Newsletter Subscription

Stay informed of the latest news and features